Skip to main content
7011 search results for:

Imipenem 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 01-05-2024 | Imipenem | News

    Imipenem/cilastatin

    Lack of efficacy
  2. 01-05-2024 | Imipenem | News

    Imipenem/cilastatin

    Acute renal failure and seizure
  3. Open Access 29-12-2023 | Imipenem | OriginalPaper

    Activity of imipenem/relebactam and comparators against KPC-producing Klebsiella pneumoniae and imipenem-resistant Pseudomonas aeruginosa

    Carbapenem-resistant Gram-negative bacilli (CRGNB) are a major public health problem, recently described by WHO as a global crisis [ 1 ]. Since nosocomial and healthcare-associated infections caused by CRGNB organisms significantly increase …

  4. Open Access 01-12-2024 | Imipenem | OriginalPaper

    The importance of meropenem resistance, rather than imipenem resistance, in defining carbapenem-resistant Enterobacterales for public health surveillance: an analysis of national population-based surveillance

    Carbapenem-resistant Enterobacterales (CRE) have been represents a global public health concern, and the importance of surveillance is well recognised [ 1 – 3 ]. Furthermore, carbapenemase-producing Enterobacterales (CPE) have been prioritised as …

  5. 01-08-2023 | Imipenem | News

    Imipenem/cilastatin

    Neutropenia: case report
  6. 01-10-2023 | Imipenem | News

    Imipenem

    Seizures: case report
  7. 01-08-2022 | Nausea | News

    Imipenem/cilastatin/quetiapine

    Various toxicities: 3 case reports
  8. Open Access 11-08-2023 | Imipenem | OriginalPaper

    Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland

    Carbapenemase-producing in Enterobacterales (CPE) represent a critical health concern worldwide, including in Switzerland, leading to very limited therapeutic options. Therefore, our aim was to evaluate the susceptibility to the novel …

  9. 01-03-2021 | Levofloxacin | News

    Imipenem/cilastatin

    No response: case report
  10. 01-04-2023 | Laminectomy | News

    Imipenem

    Lack of efficacy: case report
  11. 01-04-2023 | Fosfomycin | News

    Imipenem/cilastatin

    DRESS syndrome: case report
  12. 01-04-2023 | Imipenem | News

    Imipenem/cilastatin/isoglycyrrhizinate/polyenylphosphatidylcholine

    Lack of efficacy: case report
  13. 01-12-2021 | Imipenem | OriginalPaper

    Transcatheter Arterial Embolization Using Imipenem/Cilastatin Sodium for Chronic Low Back Pain Resistant to Conservative Treatment: A Pilot Study with 2-Year Follow-Up

    Low back pain affects people of all ages and is a leading contributor to disease burden worldwide [ 1 ]. The effects of chronic low back pain on patients vary substantially, from those who experience minimal disruption to their life through to …

  14. 01-03-2023 | Imipenem | News

    Imipenem

    Neurotoxicity: case report
  15. 27-04-2023 | Knee Osteoarthritis | EditorialNotes

    Commentary on: A Retrospective Comparison of the Efficacy of Embolization with Imipenem/Cilastatin and Microspheres in the Management of Chronic Shoulder Pain

  16. 01-12-2022 | Sarcoidosis | News

    Imipenem/methotrexate

    COVID-19, influenza H1N1 infection and treatment failure: case report
  17. 01-11-2022 | Acute Kidney Injury | News

    Imipenem/cilastatin/norepinephrine/vancomycin

    Lack of efficacy: case report
  18. 24-02-2023 | Imipenem | OriginalPaper

    A Retrospective Comparison of the Efficacy of Embolization with Imipenem/Cilastatin and Microspheres in the Management of Chronic Shoulder Pain

    Chronic shoulder pain includes various pathological entities that are often related to each other, including rotator cuff injuries, bursitis and adhesive capsulitis (AC) [ 1 , 2 ]. The first line of treatment combines analgesics, physiotherapy and …

  19. 01-05-2020 | Imipenem | ReviewPaper

    Clinical Pharmacokinetics and Pharmacodynamics of Imipenem–Cilastatin/Relebactam Combination Therapy

    On 16 July, 2019, the US Food and Drug Administration approved imipenem–cilastatin/relebactam (Recarbrio™) for the treatment of adults with complicated urinary tract infections and complicated intra-abdominal infections. This decision was based on …

  20. 01-08-2022 | Amphotericin B | News

    Imipenem/voriconazole

    No therapeutic response: case report

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.